share_log

Scryb Applauds New Bipartisan $32B Roadmap for AI Policy From U.S. Senate; Driving the Market for Scryb's AI Compliance Solution

Scryb Applauds New Bipartisan $32B Roadmap for AI Policy From U.S. Senate; Driving the Market for Scryb's AI Compliance Solution

Scryb歡迎來自美國參議院的新的跨黨派的320億美元人工智能政策路線圖;推動Scryb的人工智能合規方案市場。
newsfile ·  06/03 08:55

Toronto, Ontario--(Newsfile Corp. - June 3, 2024) - Scryb Inc. (CSE: SCYB) (OTC Pink: SCYRF) (FSE: EIY) (Scryb'' or the "Company") is pleased to share that after several months of anticipation the U.S. Senate has released a $32 Billion "Bipartisan Roadmap for AI Policy'' highlighting the support and critical need for AI regulation and governance solutions to catch up to industry. These developments further validate the expanding market opportunity and Scryb's focus in providing robust AI governance solutions to industry, and mark another step forward in the U.S. administration's long-standing commitment to AI governance, following Executive Order 14110 from October 2023.[1]

安大略省多倫多--(newsfile corp. - 2024年6月3日)--Scryb公司(CSE:SCYB)(OTC Pink: SCYRF)(FSE:EIY)(以下簡稱“公司”)很高興地分享,在經過數月的期待後,美國參議院發佈了一份320億美元的“AI政策雙方路線圖”,強調了支持和緊迫需要AI監管和治理解決方案,以趕上行業發展。這些進展進一步驗證了不斷擴大的市場機會和Scryb在爲行業提供強大的AI治理解決方案方面的專注,標誌着美國政府長期致力於AI治理的又一步實踐,緊隨2023年10月執行行政命令14110之後。[1]

The framework marks a significant development related to Artificial Intelligence ("AI") Regulation and Compliance in the United States. The recently unveiled U.S. roadmap for $32 billion, up from $1.7 billion, in funding for AI policy by 2026, further validates the critical need for robust AI governance solutions. From autonomous decision-making to idea generation, it is expected that AI will become a type of insight generator, or even become a managerial actor within organizations. As AI continues to evolve, it can also potentially take power away from humans and pose significant risks if not properly managed. Scryb's 'AI Trace-Box' will support organizations in navigating these regulatory landscapes and requirements, supporting their compliance posture and fostering trust in AI systems.[2]

框架標誌着美國人工智能(“AI”)監管和合規方面的重要進展。最近公佈的320億美元的美國政策路線圖,比之前的17億美元多了太多,進一步驗證了強大的AI治理解決方案的重要性。從自主決策到創意生成,預計AI將成爲一種見解生成器,甚至成爲組織內的管理角色。隨着AI的不斷髮展,如果不得當地管理,它也可能潛在地剝奪人類的權力並帶來重大風險。Scryb的“AI Trace-Box”將支持組織在這些監管環境和要求中進行導航,支持其合規姿態和促進對AI系統的信任。[2]

"Scryb is committed to harnessing AI's full potential while minimizing risks. As AI adoption accelerates, the world needs robust management and governance solutions to address global challenges and safety concerns. We are encouraged by recent announcements surrounding increased AI regulation and governance requirements, which continue to support and further validates the value proposition for Scryb's AI Trace Box venture," said Yoav Raiter, CEO of Scryb Inc.

“Scryb致力於發揮AI的全部潛力,同時將風險降至最低。隨着AI採用的加速,世界需要強大的管理和治理解決方案來應對全球挑戰和安全問題。我們對最近關於加強AI監管和治理要求的各種公告表示鼓舞,繼續支持和進一步驗證Scryb的AI Trace Box公司的價值主張。”尼爾·岡(Neil Gunn),臨時首席執行官表示Scryb Inc. 的CEO Yoav Raiter。

With autonomous decision-making, AI is unique in its ability to make independent decisions, posing risks if not properly managed. AI can also generate new ideas, potentially taking power away from humans and creating unforeseen challenges across industries. AI Trace-Box will offer proactive tools for compliance, aligning with guidelines from bodies like NIST and the newly approved EU AI Act. This product enhances the safety, trustworthiness, and management of AI systems, anticipating global trends in AI adoption and regulatory requirements.

作爲一種能夠獨立決策的自主決策機制,AI的風險管理非常獨特,如果不得當地管理,會帶來很大的風險。AI還可以生成新的想法,潛在地剝奪人類的權力,引發跨行業的意想不到的挑戰。AI Trace-Box將爲合規性提供主動性工具,符合NISt等機構的指導方針和新批准的歐盟AI法規。該產品增強了AI系統的安全性、可信度和管理性,預測全球AI採用和監管要求的全球趨勢。

AI Regulation, Requirements and Compliance Market

AI法規,要求和合規市場

NIST leads AI best practice and guidelines in the U.S. and will implement security, trust and transparency requirements as AI adoption grows, as part of the Executive Order implementation. Given the complexity of AI risks, real-time monitoring is essential for effective governance. The White House Executive Order from October 30, 2023, tasked NIST to develop and release various AI safety and security guidelines, and many of these guidelines have been released already for public comments. These initiatives include developing AI Risk Management and Secure Software AI Development Frameworks (NIST SP 800-218A)[3] and establishing benchmarks for evaluating and auditing AI capabilities. The new EU AI Act, approved in early 2024, is the most comprehensive AI regulation to date, categorizing AI systems by risk and imposing stringent rules on high-risk systems before they enter the EU market.

NISt在美國領導AI最佳實踐和指南,並隨着AI採用的增長實施安全、信任和透明度要求,作爲行政命令實施的一部分。鑑於AI風險的複雜性,實時監測對於有效的治理至關重要。白宮於2023年10月30日發佈的行政命令,要求NISt制定併發布各種AI安全和安全指南,其中許多指南已經公開發表評論。這些舉措包括開發AI風險管理和安全軟件AI開發框架(NISt SP 800-218A),並建立評估和審計AI能力的基準。新的歐盟AI法案於2024年初獲得批准,是迄今爲止最全面的AI法規,將高風險系統分爲類別,並對其進入歐盟市場前實施嚴格的規定。[3]AI軟件支出預計將在2027年增長至2980億美元,CAGR爲19.1%。僅AI服務的預測市場規模將達到4430億美元,在2023年至2027年期間的複合年增長率(CAGR)爲16.9%。

AI software spending is projected to grow to $298 billion by 2027, with a CAGR of 19.1%.[4] AI services alone are forecast to be a $443 billion market by 2027, with a compound annual growth rate (CAGR) of 16.9% from 2023 through 2027.[5]

預計到2027年,AI軟件支出將增長至2980億美元,年複合增長率爲19.1%。密切繼發性IONCM是目前Urology領域最棘手的問題之一,而TLX250-CDx的全球性Phase III臨床研究證實了該檢測工具的高靈敏度和特異性,爲受治患者的有效治療提供了重要依據。AI服務本身預計將成爲2027年的440億美元市場,複合年增長率(CAGR)爲2023年至2027年的16.9%。[5]

About Scryb Inc.

關於Scryb公司

Scryb, a leading venture builder, specializes in the development and scaling of high-growth, disruptive businesses within the sectors of applied AI, digital health, cybersecurity, and biotech. The approach at Scryb centers on leveraging deep industry expertise to shape and drive the future of technology. Among its notable ventures is a cybersecurity company where Scryb maintains majority ownership. For further information about Scryb's innovative projects and vision, please visit our website at .
Contact:
W. Clark Kent
President
Office. 647-872-9982neo
TF. 1-844-247-6633
Email: info@scryb.ai

Scryb是一家領先的風險投資組合公司,專注於應用人工智能、數字醫療、網絡安全和生物技術等領域中高增長和顛覆性的企業的開發和擴張。Scryb的方法集中在利用深厚的行業專業知識來塑造和推動技術的未來。在其著名的風險投資中,Scryb擁有一家網絡安全公司,Scryb保持着大多數所有權。有關Scryb創新項目和願景的更多信息,請訪問我們的網站。
聯繫方式:
W. Clark Kent
總裁
辦公室。647-872-9982neo
TF.1-844-247-6633
辦公室。 647-872-9982 neo 電子郵件:info@scryb.ai

Forward-looking Information Cautionary Statement

前瞻性信息警示聲明

Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. There are no assurances that the commercialization plans for the technology described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, which filings are available at

除了歷史事實陳述外,本新聞發佈會還包含某些適用證券法的“前瞻性信息”。前瞻性信息經常以“計劃”、“預期”、“項目”、“打算”、“相信”、“預測”、“估計”和其他類似的詞語,或者陳述特定事件或條件“可能”或“將要”發生等方式進行描述。前瞻性陳述是基於陳述發表日期的意見和估計,並受到各種風險、不確定性和其他因素的影響,如果在前瞻性陳述中預計的事件或結果實際發生或實現,會導致實際事件或結果與預期的事件或結果發生重大差異。包括但不限於監管批准方面的延遲或不確定性,包括CSE的延遲或不確定性。前瞻性信息具有不確定性,包括公司無法控制的因素。 如果在本新聞發佈會描述的技術的商業化計劃不按照既定的條款或時間框架生效,我們不保證商業化計劃的經濟效益。 除非法律規定,否則如果情況或管理估計或意見發生變化,我們不會更新前瞻性信息。 您受到警告不要過分依賴前瞻性陳述。識別可能影響財務業績的風險和不確定性的其他信息包含在公司向加拿大證券監管機構提交的備案文件中,該備案文件可在以下地點獲得。


[1]

[1]

[2]

[2]

[3]

[3]

[4]

密切繼發性IONCM是目前Urology領域最棘手的問題之一,而TLX250-CDx的全球性Phase III臨床研究證實了該檢測工具的高靈敏度和特異性,爲受治患者的有效治療提供了重要依據。

[5]

[5]

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論